Exhibit 10.1
OMNIBUS AMENDMENT AGREEMENT
This Omnibus Amendment Agreement (this “Agreement”), dated November 20, 2026, is by and between Q/C Technologies, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”).
WITNESSETH
Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Series G Purchase Agreement”), and each of the investors signatory thereto, pursuant to which the Company issued and sold to the Investor (i) shares of the Company’s Series G Convertible Preferred Stock, par value $0.001 per share (the “Series G Preferred Stock”), the terms of which are set forth in the Certificate of Designations of Series G Convertible Preferred Stock (as amended, the “Series G Certificate of Designations”), (ii) accompanying warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), with a term of five (5) years from the date of issuance (as amended, the “Series G Long-Term Warrants”), and (iii) accompanying warrants to purchase shares of the Company’s Common Stock, with an initial term of eighteen (18) months from the date of issuance (as amended, the “Series G Short-Term Warrants” and, the Series G Long-Term Warrants, the Series G Short-Term Warrants, the Series G Purchase Agreement, and the Series G Certificate of Designations, collectively, the “Series G Transaction Documents”);
Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of September 2, 2025 (the “Series H Purchase Agreement”), and each of the investors signatory thereto, pursuant to which the Company issued and sold to the Investor (i) shares of the Company’s Series H Convertible Preferred Stock, par value $0.001 per share (the “Series H Preferred Stock”), the terms of which are set forth in the Certificate of Designations of Series H Convertible Preferred Stock (as amended, the “Series H Certificate of Designations”), and (ii) accompanying warrants to purchase shares of the Company’s Common Stock (the “Series H Warrants” and, the Series H Warrants, the Series H Purchase Agreement, and the Series H Certificate of Designations, collectively, the “Series H Transaction Documents”);
WHEREAS, pursuant to Section 31(b) of the Series G Certificate of Designations, the Series G Certificate of Designations or any provision hereof may be amended by written consent of the Required Holders (as defined therein) voting separately as a single class;
WHEREAS, pursuant to Section 32(b) of the Series H Certificate of Designations, the Series H Certificate of Designations or any provision hereof may be amended by written consent of the Required Holders (as defined therein) voting separately as a single class;
WHEREAS, the Company and the Investor desire to amend the Series G Certificate of Designations and the Series H Certificate of Designations as described herein;
WHEREAS, the Investor represents that, as of the date hereof, it holds at least a majority of the outstanding shares of each of the Series G Preferred Stock and the Series H Preferred Stock and, in each case, thereby constitutes the Required Holders (as defined in each of the Series G Certificate of Designations and the Series H Certificate of Designations);
WHEREAS, pursuant to Section 11 of the Series G Long-Term Warrant, the terms of the Series G Long-Term Warrants may be amended only if the Company has obtained the written consent of such warrant holder;
NOW, THEREFORE, in consideration of the premises and mutual covenants and obligations hereinafter set forth, the parties hereto, intending legally to be bound, hereby agree as follows:
1. Definitions. Capitalized terms used herein but not otherwise defined herein shall have the respective meanings given such terms in the Series G Certificate of Designations, Series H Certificate of Designations, and the Series G Long-Term Warrants, as applicable.
2. Amendment to Series G Certificate of Designations. The parties hereto hereby agree to amend the terms of the Series G Preferred Stock as set forth in the Certificate of Amendment to the Certificate of Designations of the Series G Preferred Stock in the form attached hereto as Exhibit A (the “Series G Amendment”). The Company shall promptly file the Series G Amendment with the Secretary of State of the State of Delaware and provide a copy thereof to the Investor promptly after such filing.
3. Amendment to Series H Certificate of Designations. The parties hereto hereby agree to amend the terms of the Series H Preferred Stock as set forth in the Certificate of Amendment to the Certificate of Designations of the Series H Preferred Stock in the form attached hereto as Exhibit B (the “Series H Amendment”). The Company shall promptly file the Series H Amendment with the Secretary of State of the State of Delaware and provide a copy thereof to the Investor promptly after such filing.
4. Amended Series G Long-Term Warrants.
(i) Effective as of November 20, 2026, Section 11 of the Series G Long-Term Warrant is hereby amended to delete the words “(other than Section 1(f))” and, as so amended and restated, reads in its entirety as follows:
11. Amendment and Waiver. Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party.
(ii) Effective as of November 20, 2026, Section 1(f)(i) of the Series G Long-Term Warrant is hereby amended and restated in its entirety as follows (emphasis added):
(i) * Beneficial Ownership*. The Company shall not effect the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 49.99% (the “Maximum Percentage”) of the Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 1(f)(i). For purposes of this Section 1(f)(i), beneficial ownership shall be calculated in accordance with Section 13(d) of the 1934 Act. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the 1934 Act and the rules and regulations promulgated thereunder. For purposes of determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public announcement by the Company or (z) any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock outstanding (the “Reported Outstanding Share Number”). If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder’s beneficial ownership, as determined pursuant to this Section 1(f)(i), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be acquired pursuant to such Exercise Notice (the number of shares by which such purchase is reduced, the “Reduction Shares”) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61st) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 49.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of SPA Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f)(i) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 1(f)(i) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived (provided that such limitation may be waived, increased or otherwise modified by written agreement of the Company and the Holder) and shall apply to a successor holder of this Warrant. Nothing in this Section 1(f)(i) shall limit or otherwise affect any right of the Holder to receive any cash payment, Black Scholes Value or other consideration with respect to any portion of this Warrant that cannot then be exercised by reason of this Section 1(f)(i).
5. Counterparts; Facsimile Execution. This Agreement may be executed in one or more counterparts (including by electronic mail, in PDF or by DocuSign or similar electronic signature), all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
6. Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Investor from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s obligations to the Investor or to enforce a judgment or other court ruling in favor of the Investor.
7. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.
8. Terms and Conditions. Except as modified and amended herein, all of the terms and conditions of the Series G Transaction Documents, the Series H Transaction Documents and the Series G Long-Term Warrants shall remain in full force and effect.
9. Representations and Warranties of the Company. The Company represents and warrants to the Investor that: (a) the Company has all requisite corporate power and authority to enter into and perform this Agreement, the Series G Amendment and the Series H Amendment; (b) no consent, approval or vote of any holder of capital stock of the Company (other than the Required Holders) or of any other holder of Series G Long-Term Warrants; and (c) this Agreement does not conflict with or result in a breach of the Certificate of Incorporation, the Company’s bylaws, any Series G Transaction Document, any Series H Transaction Document, or any agreement with any other holder of the Company’s securities.
[Signature pages follow immediately]
[Company Signature Page to Omnibus Amendment Agreement]
IN WITNESS WHEREOF, the undersigned has executed and delivered this Agreement as of the date first above written.
| Company: | ||
| Q/C Technologies, Inc. | ||
| By: | /s/ Joshua Silverman | |
| Name: | Joshua Silverman | |
| Title: | Executive Chairman |
[Investor Signature Page to Omnibus Amendment Agreement]
In witness whereof, the undersigned has executed and delivered this Agreement as of the date first above written.
| Investor: | ||
| PharmaCyte Biotech, Inc. | ||
| By: | /s/ Carlos Trujillo | |
| Name: | Carlos Trujillo | |
| Title: | Chief Financial Officer |